Evidence map›Paper›PMID 41361476›Full record

ArticleThrombosis journal2025

The correlation of lupus anticoagulant and anticardiolipin antibodies with hematological parameters and clinical findings in sickle cell disease at steady state phase.

Mohammed Aw Almorish, Ahmed M E Elkhalifa, Moataz Mohamedalhasan Ali, Isameldin Mohamed Abdalla Hamad, Omer M Aburaida, Rabei M Elbadry, Yasir S Kaloda, Elfatih Mirghani M Salih, Khaled Mohammed Al-Sayaghi, Mohammed A Hameed Albalawi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mohammed Aw AlmorishDepartment of Hematology, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen. m.almorish@su.edu.ye.ORCID http://orcid.org/0000-0001-5296-7115
Ahmed M E ElkhalifaDepartment of Public Health, College of Health Sciences, Saudi Electronic University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-2660-5054
Moataz Mohamedalhasan AliDepartment of Pathology, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.
Isameldin Mohamed Abdalla HamadDepartment of Physiology, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.
Omer M AburaidaDepartment of Pediatric, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.
Rabei M ElbadryDepartment of Pathology, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.
Yasir S KalodaDepartment of Physiology, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.
Elfatih Mirghani M SalihDepartment of Pediatric, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.
Khaled Mohammed Al-SayaghiDepartment of Medical Surgical Nursing, Taibah University, Madinah, Saudi Arabia.
Mohammed A Hameed AlbalawiDepartment of Internal Medicine, College of Medicine, Taibah University, Madinah, Saudi Arabia.
Maher M AljohaniDepartment of Pathology, College of Medicine, Taibah University, Madinah, Saudi Arabia.
Burhanudin SahaDepartment of Medical Laboratory, King Abdullah Medical City, Makkah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent therapeutic interventions for Sickle Cell Disease (SCD) have improved patient survival; however, the clinical determinants of elevated autoantibody prevalence and related complications in patients with SCD remain insufficiently elucidated.

objectiveThis study aimed to examine the frequency of lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti-beta2 glycoprotein I antibodies (anti- β2GPI) in patients with SCD at steady state phase to evaluate their possible correlations with hematological factors and clinical complications.

methodsThis cross-sectional study involving 92 SCD patients in a steady state phase was conducted. Blood specimens were obtained for complete blood count (CBC), in conjunction with the identification of IgG for aCL and anti-β2GPI utilizing enzyme-linked immunosorbent assay (ELISA) and the assessment of LA through the Diluted Russell Viper Venom Time (dRVVT).

resultsThe prevalence of LA, aCL, and anti-β2GPI (IgG) in SCD patients at steady state was 29.4%, 16.3%, and 5.4%, respectively. A correlation was found between LA and chronic leg ulcers, history of thrombosis, decreased platelet counts (PLT), and increased mean platelet volume (MPV) in SCD patients. Furthermore, aCL (IgG) exhibited a significant association with chronic leg ulcers, history of thrombosis, elevated Hemoglobin (Hb) levels, increased red blood cell count (RBC), and higher red cell distribution width (RDW) in SCD patients at steady state phase.

conclusionThis research elucidates the incidence of LA and aCL in SCD patients during steady state, linking these autoantibodies to hematological parameters and clinical complications; thus, prospective assessments of aPL in SCD patients are essential.

Indexed as

anti-beta2 glycoprotein I antibodiesAnticardiolipin antibodiesChronic leg ulcersLupus anticoagulantSickle cell diseaseThrombosis

Identifiers

PMID41361476
PMCPMC12687473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.